Literature DB >> 16504819

The definition and measurement of disease modification in inflammatory rheumatic diseases.

Daniel Aletaha1, Josef S Smolen.   

Abstract

This article focuses on measures that are used to evaluate disease activity, damage, and function in three major inflammatory musculoskeletal disorders. The instruments used in rheumatoid arthritis, where most of the methodologic work has been done, are extensively discussed and instruments for the respective domains in psoriatic arthritis and ankylosing spondylitis are likewise presented.

Entities:  

Mesh：

Year:  2006        PMID： 16504819     DOI： 10.1016/j.rdc.2005.09.005

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN： 0889-857X            Impact factor:   2.670


  38 in total

1.  Consensus statement on the use of rituximab in patients with rheumatoid arthritis.

Authors:  J S Smolen; E C Keystone; P Emery; F C Breedveld; N Betteridge; G R Burmester; M Dougados; G Ferraccioli; U Jaeger; L Klareskog; T K Kvien; E Martin-Mola; K Pavelka
Journal:  Ann Rheum Dis       Date:  2006-10-26       Impact factor: 19.103

2.  Toward development of a fibromyalgia responder index and disease activity score: OMERACT module update.

Authors:  Philip J Mease; Daniel J Clauw; Robin Christensen; Leslie J Crofford; R Michael Gendreau; Susan A Martin; Lee S Simon; Vibeke Strand; David A Williams; Lesley M Arnold
Journal:  J Rheumatol       Date:  2011-07       Impact factor: 4.666

Review 3.  2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.

Authors:  Jasvinder A Singh; Daniel E Furst; Aseem Bharat; Jeffrey R Curtis; Arthur F Kavanaugh; Joel M Kremer; Larry W Moreland; James O'Dell; Kevin L Winthrop; Timothy Beukelman; S Louis Bridges; W Winn Chatham; Harold E Paulus; Maria Suarez-Almazor; Claire Bombardier; Maxime Dougados; Dinesh Khanna; Charles M King; Amye L Leong; Eric L Matteson; John T Schousboe; Eileen Moynihan; Karen S Kolba; Archana Jain; Elizabeth R Volkmann; Harsh Agrawal; Sangmee Bae; Amy S Mudano; Nivedita M Patkar; Kenneth G Saag
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-05       Impact factor: 4.794

Review 4.  Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges.

Authors:  Josef S Smolen; Daniel Aletaha
Journal:  Nat Rev Rheumatol       Date:  2015-02-17       Impact factor: 20.543

5.  High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register.

Authors:  Florenzo Iannone; Elisa Gremese; Gaia Gallo; Piercarlo Sarzi-Puttini; Costantino Botsios; Francesco Trotta; Stefania Gasperini; Mauro Galeazzi; Silvano Adami; Fabrizio Cantini; Marco Sebastiani; Roberto Gorla; Antonio Marchesoni; Annarita Giardina; Rosario Foti; Angiola Mele; Eleonora Bruschi; Gianluca Bagnato; Gian Luca Erre; Giovanni Lapadula
Journal:  Clin Rheumatol       Date:  2013-08-18       Impact factor: 2.980

6.  The impact of C677T and A1298C MTHFR polymorphisms on methotrexate therapeutic response in East Bohemian region rheumatoid arthritis patients.

Authors:  Tomas Soukup; Martin Dosedel; Petr Pavek; Jana Nekvindova; Ivan Barvik; Iva Bubancova; Petr Bradna; Ales Antonin Kubena; Alejandro Fernández Carazo; Tomas Veleta; Jiri Vlcek
Journal:  Rheumatol Int       Date:  2015-01-25       Impact factor: 2.631

7.  Disease modification in gout: a qualitative study of gout expert rheumatologists.

Authors:  Jasvinder A Singh
Journal:  Rheumatol Adv Pract       Date:  2022-01-03

Review 8.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.

Authors:  Josef S Smolen; Robert Landewé; Ferdinand C Breedveld; Maxime Dougados; Paul Emery; Cecile Gaujoux-Viala; Simone Gorter; Rachel Knevel; Jackie Nam; Monika Schoels; Daniel Aletaha; Maya Buch; Laure Gossec; Tom Huizinga; Johannes W J W Bijlsma; Gerd Burmester; Bernard Combe; Maurizio Cutolo; Cem Gabay; Juan Gomez-Reino; Marios Kouloumas; Tore K Kvien; Emilio Martin-Mola; Iain McInnes; Karel Pavelka; Piet van Riel; Marieke Scholte; David L Scott; Tuulikki Sokka; Guido Valesini; Ronald van Vollenhoven; Kevin L Winthrop; John Wong; Angela Zink; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2010-05-05       Impact factor: 19.103

9.  Acceptable quality of life and low disease activity achievable among transition phase patients with rheumatic disease.

Authors:  Heikki Relas; Silja Kosola
Journal:  Clin Rheumatol       Date:  2018-10-29       Impact factor: 2.980

10.  American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.

Authors:  David T Felson; Josef S Smolen; George Wells; Bin Zhang; Lilian H D van Tuyl; Julia Funovits; Daniel Aletaha; Cornelia F Allaart; Joan Bathon; Stefano Bombardieri; Peter Brooks; Andrew Brown; Marco Matucci-Cerinic; Hyon Choi; Bernard Combe; Maarten de Wit; Maxime Dougados; Paul Emery; Daniel Furst; Juan Gomez-Reino; Gillian Hawker; Edward Keystone; Dinesh Khanna; John Kirwan; Tore K Kvien; Robert Landewé; Joachim Listing; Kaleb Michaud; Emilio Martin-Mola; Pamela Montie; Theodore Pincus; Pamela Richards; Jeffrey N Siegel; Lee S Simon; Tuulikki Sokka; Vibeke Strand; Peter Tugwell; Alan Tyndall; Desirée van der Heijde; Suzan Verstappen; Barbara White; Frederick Wolfe; Angela Zink; Maarten Boers
Journal:  Arthritis Rheum       Date:  2011-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.